Pancreatic lipase inhibitors can impact the activity of pancreatic lipase, reduce the hydrolysis and absorption of dietary fat and have a preeminent behavior on the treatment of obesity and prevention of its complications. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.